By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Allergan plc 

U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Parsippany  New Jersey  07054  U.S.A.
Phone: 862-261-7000 Fax: n/a


Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.

We’re Looking for the World’s Best

At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.

At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.

Commit to your future and join us. Learn more about our exciting career opportunities at

Key Statistics

Ownership: Public

Web Site: Allergan
Symbol: AGN



Elan Pharmaceuticals 

CeNes Pharmaceuticals (U.S.) 

PanVera LLC 

Pharmagene Laboratories Limited  Phase ZERO(TM) products and services.

Acadia  Discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain.

Acadia  Develop and commercialize selective muscarinic drugs for the treatment of glaucoma.

Acadia  The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.

Company News
Allergan (AGN) Eyes Smaller M&A Deals After $40.5 Billion Sale of Its Generics Unit to Teva (TEVA) is Completed 5/24/2016 7:29:02 AM
Allergan (AGN)'s BOTOX Vista (Botulinum Toxin Type A) Receives National Marketing Authorisation In Japan For Treatment Of Crow's Feet Lines In Adult Patients 5/24/2016 6:14:45 AM
Allergan (AGN) Announces FDA Acceptance Of NDA Filing For Oxymetazoline HCI Cream 1.0% 5/24/2016 6:12:17 AM
Allergan (AGN) Launches 'IBS-D On Tract,' New Online Resource To Support Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D) 5/23/2016 7:24:40 AM
Allergan (AGN) To Present At The Bernstein 32nd Annual Strategic Decisions Conference 5/19/2016 9:24:41 AM
Allergan (AGN) To Present At The UBS 2016 Global Healthcare Conference 5/18/2016 7:43:03 AM
Allergan (AGN) Reinforces Commitment To Hypertension Management With Four Poster Presentations At American Society of Hypertension 2016 5/16/2016 8:22:04 AM
Allergan (AGN) Shows Off Positive Mid-Stage Data for Oculeve Intranasal Tear Neurostimulator 5/16/2016 5:57:04 AM
Allergan (AGN) And Gedeon Richter (RIG2.F) To Present Data On Cariprazine At The American Psychiatric Association Annual Meeting 5/12/2016 8:52:48 AM
Allergan (AGN) Reworking Its Executive Team, Outlines $10 Billion Stock Buyback as Q1 Revenue Falls Short 5/11/2016 7:15:44 AM